BAIN CAPITAL / KOHLBERG acquires PCI PHARMA GROUP (2025)

Deal facts

Buyer: BAIN CAPITAL / KOHLBERG
Target: PCI PHARMA GROUP
Deal value: Not disclosed
Announced: 3 September 2025
Status: In review
Sector: Healthcare
Country: Not stated
Consideration: Not stated

Sources

EU_DG_COMP

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

29 Sept 2025CMA invitation to comment
BAIN CAPITAL / KOHLBERG / PCI PHARMA GROUP
BAIN CAPITAL / KOHLBERG / PCI PHARMA GROUP
EU DG COMP

OpinionExit Mode editorial

We see a clear signal in the announcement that Bain Capital, alongside Kohlberg, is moving to acquire PCI Pharma Group. This deal, confirmed on 3 September 2025, places a major private equity consortium into the healthcare sector with a specific focus on contract pharmaceutical services. The transaction remains in review, which is the standard procedural stance for a deal of this magnitude involving global capital and critical supply chain assets. For the SME founder watching from the sidelines, this confirms that institutional investors continue to view specialised healthcare logistics as a resilient asset class, even as broader economic conditions shift.

The structure of this acquisition as a private equity buyout introduces specific commercial mechanics that founders must understand. When a buyer like Bain or Kohlberg steps in, the deal often hinges on rigorous due diligence regarding change-of-control covenants within existing customer contracts. In the pharmaceutical sector, regulatory clearance is not a mere formality; it is a substantive hurdle. The Competition and Markets Authority will likely scrutinise the transaction to ensure no anti-competitive consolidation occurs within the UK supply chain. Furthermore, the in-review status suggests that regulatory approval or specific conditions precedent must be satisfied before completion, a phase where many deals stall if the target cannot demonstrate sufficient operational independence or compliance history.

We believe the strategic intent here is to consolidate a fragmented market. The buyer is not merely purchasing revenue; they are acquiring a platform to integrate and scale. For founders in this space, the presence of such a buyer validates the sector but also raises the bar for operational excellence. The lack of a disclosed value in the announcement is typical for private transactions, yet it underscores that the premium lies in the strategic fit rather than immediate financial metrics. The focus will shift quickly to how the new owners manage the integration of PCI Pharma Group without disrupting the critical services they provide to pharmaceutical manufacturers.

Your immediate action this week is to audit your own customer contracts for change-of-control clauses. Identify any provisions that might trigger a right of termination or require third-party consent if a private equity firm acquires your business. Do not wait for a term sheet to understand these constraints, as they can derail a deal at the eleventh hour.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More pe acquisition deals More from BAIN CAPITAL / KOHLBERG All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

16 April 2026Firm intentionHealthcare

CCP PAW 2 LIMITED to acquire Animalcare Group plc

CCP PAW 2 LIMITED has agreed to acquire Animalcare Group plc in a private equity acquisition valued at 235.2 million GBP. The transaction, announced on 16 April 2026, in…

Buyer: CCP PAW 2 LIMITED
Target: Animalcare Group plc
Deal value: GBP 235,200,000
Deal type: pe acquisition

Read deal Healthcare deals pe acquisition deals United Kingdom deals

22 January 2026In reviewHealthcare

BLACKSTONE / TPG to acquire HOLOGIC

BLACKSTONE / TPG and HOLOGIC entered the Exit Mode archive.

Buyer: BLACKSTONE / TPG
Target: HOLOGIC
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Healthcare deals pe acquisition deals In review deals

9 July 2025In reviewHealthcare

KKR to acquire KARO HEALTHCARE

KKR has agreed to acquire KARO HEALTHCARE in a private equity acquisition. The transaction was announced on 9 July 2025. The target operates within the NaceV2Sector_N_72…

Buyer: KKR
Target: KARO HEALTHCARE
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Healthcare deals pe acquisition deals In review deals

11 May 2025In reviewHealthcare

HELLMAN & FRIEDMAN / CVC to acquire MEHILÄINEN

Hellman & Friedman and CVC have agreed to acquire Mehiläinen, a Finnish healthcare provider, in a private equity acquisition announced on 11 May 2025. The transaction in…

Buyer: HELLMAN & FRIEDMAN / CVC
Target: MEHILÄINEN
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Healthcare deals pe acquisition deals Finland deals

4 May 2025In reviewHealthcare

MADISON DEARBORN PARTNERS / THOMA BRAVO to acquire NEXTGEN HEALTHCARE

MADISON DEARBORN PARTNERS and THOMA BRAVO have agreed to acquire NEXTGEN HEALTHCARE in a private equity acquisition. The transaction was announced on 4 May 2025. The tar…

Buyer: MADISON DEARBORN PARTNERS / THOMA BRAVO
Target: NEXTGEN HEALTHCARE
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Healthcare deals pe acquisition deals In review deals

Buyer history